Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Cash from Operations of 14730000.0 for Q1 2026, up 66.35% year-over-year from 8854666.47 in Q1 2025, and up 14.52% quarter-over-quarter from 17233000.0 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Cash from Operations for 17 consecutive years, with 14730000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 66.35% year-over-year to 14730000.0; the TTM figure through Mar 2026 stood at 38803000.0 (up 76.82% YoY), while the FY2025 annual figure was 67851000.0, up 62.05% from the prior year.
- Cash from Operations rose to 14730000.0 in Q1 2026 per LXRX's latest filing, from 17233000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 16993000.0 in Q2 2025 and bottomed at 55130000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 30124058.82 across 5 years, with a median of 24422000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 134.35% — and 2025, when it soared 135.01%.
- Lexicon Pharmaceuticals' Cash from Operations stood at 21569000.0 in 2022, then sank by 134.35% to 50548000.0 in 2023, then soared by 57.48% to 21491000.0 in 2024, then grew by 19.81% to 17233000.0 in 2025, then rose by 14.52% to 14730000.0 in 2026.
- Business Quant data shows LXRX's Cash from Operations at 14730000.0 in Q1 2026, 17233000.0 in Q4 2025, and 23833000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -9.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.19 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Jun 30, 2024 | -48.54 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Dec 31, 2023 | -50.55 Mn |
| Sep 30, 2023 | -41.62 Mn |
| Jun 30, 2023 | -38.12 Mn |
| Mar 31, 2023 | -31.61 Mn |
| Dec 31, 2022 | -21.57 Mn |
| Sep 30, 2022 | -19.44 Mn |
| Jun 30, 2022 | -24.42 Mn |
| Mar 31, 2022 | -23.42 Mn |
| Dec 31, 2021 | -22.83 Mn |
| Sep 30, 2021 | -17.15 Mn |